anticorps apg4a, anticorps autl2, anticorps F6E13.27, anticorps APG4A, anticorps zgc:111958, anticorps Aut2a, anticorps AUTL2, anticorps AI627006, anticorps AV169859, anticorps Apg4a, anticorps Atg4al, anticorps Autl2, anticorps Atg4a, anticorps autophagy related 4A cysteine peptidase L homeolog, anticorps autophagy related 4A cysteine peptidase, anticorps Peptidase family C54 protein, anticorps ATG4 autophagy related 4 homolog A (S. cerevisiae), anticorps autophagy related 4A, cysteine peptidase, anticorps atg4a.L, anticorps ATG4A, anticorps AT2G44140, anticorps atg4a, anticorps Atg4a
Sujet
Macroautophagy is the major inducible pathway for the general turnover of cytoplasmic constituents in eukaryotic cells, it is also responsible for the degradation of active cytoplasmic enzymes and organelles during nutrient starvation. Macroautophagy involves the formation of double-membrane bound autophagosomes which enclose the cytoplasmic constituent targeted for degradation in a membrane bound structure, which then fuse with the lysosome (or vacuole) releasing a single-membrane bound autophagic bodies which are then degraded within the lysosome (or vacuole). APG4A is a cysteine protease required for autophagy, which cleaves the C-terminal part of either MAP1LC3, GABARAPL2 or GABARAP, allowing the liberation of form I. A subpopulation of form I is subsequently converted to a smaller form (form II). Form II, with a revealed C-terminal glycine, is considered to be the phosphatidylethanolamine (PE)-conjugated form, and has the capacity for the binding to autophagosomes. Preferred substrate is GABARAPL2 followed by MAP1LC3A and GABARAP.